Interim results of Phase III clinic trials show that the inactivated COVID-19 vaccine developed by China National Biotec Group (CNBG), which is affiliated with Sinopharm, has an efficacy of 79.34 percent, according to a statement released by Beijing Institute of Biological Products. 

The statement said the vaccine offers a good level of safety after inoculation, while the data has met relevant technical standards of both the World Health Organization and the Chinese authorities.

"All patients produced high-tier antibodies and the neutralizing antibody positive conversion rate was 99.52 percent," read the statement. 

The company has officially filed an application with the National Medical Products Administration for conditional listing, the statement added.